Over the last 12 months, two Electra Therapeutics, Inc. insiders picked up shares with their own money, about $40 million in total, and none of them sold.
GORDON CARL L (Director) made the biggest buy, worth around $15 million.
Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | GORDON CARL L | Director | Buy | 333,333 | $15.00 | $5.0M | SEC |
| Sep 23, 2026 | GORDON CARL L | Director | Buy | 1,000,000 | $15.00 | $15.0M | SEC |
| Sep 23, 2026 | OrbiMed Capital GP VII LLC | Director | Buy | 1,000,000 | $15.00 | $15.0M | SEC |
| Sep 23, 2026 | OrbiMed Capital GP VII LLC | Director | Buy | 333,333 | $15.00 | $5.0M | SEC |
In the last 12 months Electra Therapeutics, Inc. insiders made open-market purchases worth about $40 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in ETRA was filed on 2026-09-23.
No congressional trades in ETRA were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).